Niagen Bioscience Inc
HealthcareNASDAQ:NAGE · NASDAQ Capital Market
+$0.02 today
Vol 0.47M · Avg 0.97M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
22.7%
avg -56.7%
ROIC
15.6%
avg -45.9%
ROA
16.3%
avg -28.7%
Analysis
ROE is currently the strongest return metric at 22.7% versus its period average of -56.7%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Robert N. Fried | Chief Executive Officer & Director | $1.21M | — | 66 | $1.06M | 1.33% |
Ozan Pamir | Chief Financial Officer & Principal Accounting Officer | $648,236.00 | — | 34 | $62,131.00 | 0.08% |
Carlos Lopez | Senior Vice President & General Counsel | $480,029.00 | — | 45 | $41,420.00 | 0.05% |
James Lee | Controller | $286,491.00 | — | 50 | — | — |
Frank Louis Jaksch Jr. | Co-Founder & Chairman | $70,000.00 | — | 58 | $20,000.00 | 0.03% |
Lauren Rittman-Borzansky | Assistant Controller | — | — | — | — | — |
Michiko Kelley | Chief Marketing Officer | — | — | — | — | — |
Wesley Yu | Vice President of Finance | — | — | — | $20,000.00 | 0.03% |
Andrew Shao | Senior Vice President of Global Regulatory & Scientific Affairs | — | — | — | — | — |
Kendall Knysch | Head of Media Relations & Partnerships | — | — | — | — | — |
Chu Yan | Managing Director of Asia Pacific | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$45,616.43
Sells
0
$0.00
Net Sentiment
+$45,616.43
Net buying
Most Active
Pamir Ozan
2 transactions
| Date | Insider | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| Nov 14, 2025 | Pamir Ozan Direct | Buy | 4.5K | $6.81 | $30,406.39 | |
| Nov 14, 2025 | Pamir Ozan Indirect | Buy | 2.2K | $6.85 | $15,210.03 |
Analysis
Insiders reported 2 buys worth $45,616.43 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $45,616.43. Pamir Ozan was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | +15.5% | +20.6% (13yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +15.5% over three years. Forward estimates point to Revenue at +20.6% (13yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
KalVista Pharmaceuticals, Inc.
NASDAQ:KALV
$1.44B
Ventyx Biosciences, Inc.
VTYX
$1.00B
Corvus Pharmaceuticals, Inc.
NASDAQ:CRVS
$1.00B
Olema Pharmaceuticals, Inc.
NASDAQ:OLMA
$862.12M
Zevra Therapeutics, Inc.
NASDAQ:ZVRA
$747.81M
Rigel Pharmaceuticals, Inc.
NASDAQ:RIGL
$607.79M
Prothena Corporation plc
NASDAQ:PRTA
$431.91M
REGENXBIO Inc.
NASDAQ:RGNX
$344.31M
Keros Therapeutics, Inc.
NASDAQ:KROS
$324.78M
Akebia Therapeutics, Inc.
NASDAQ:AKBA
$248.00M
Who manages NAGE?
Niagen Bioscience Inc (NAGE) lists 11 active executives. The top listed executive is Robert N. Fried, Chief Executive Officer & Director.
Are NAGE insiders buying or selling?
Recent insider activity shows net buying of $5.02M.
Explore More
Continue the stock analysis
Jump to another research area for this company.